Research analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research note issued to investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Performance
Shares of AKTX opened at $0.87 on Friday. Akari Therapeutics has a 12 month low of $0.86 and a 12 month high of $4.40. The company has a 50-day moving average price of $1.15 and a two-hundred day moving average price of $2.02.
Akari Therapeutics Company Profile
Read More
- Five stocks we like better than Akari Therapeutics
- What is MarketRank™? How to Use it
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- How to Use the MarketBeat Stock Screener
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- Best Stocks Under $10.00
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.